lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics

SAN DIEGO, June 10, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), aligned with its commitments to advance the power of genomics, today published its annual Corporate Social Responsibility (CSR) Report. The report spotlights the ways Illumina is making precision health more accessible than ever before, and its ongoing work to empower people and communities, embed sustainability across its business, operate responsibly, and lead with integrity.

"At Illumina, we work relentlessly in our mission to improve human health by unlocking the power of the genome, and our CSR strategy is an essential part of that," said Jacob Thaysen, CEO of Illumina. "Our innovation has driven incredible breakthroughs—but those breakthroughs only matter if they can be accessed. Our CSR efforts are designed to drive greater access to genomics technologies and improve health equity for billions of people around the world. We continue to take meaningful steps to champion patients, communities, employees, and the planet as we work to create a healthier and more sustainable future."

2024 highlights

• Making genomics affordable and accessible: Integrating genomics across the care continuum is critical to positive health outcomes, but gaps in health insurance coverage continue to put genomic testing out of reach for many. In 2024, Illumina's advocacy efforts supported the expansion of health care coverage for genomic testing to an additional 100 million people compared to 2023, resulting in a total of 1.4 billion lives covered.
• Significantly reducing packaging and increasing product sustainability efforts: In 2024, Illumina achieved an 80% reduction in packaging since 2019, surpassing its 2030 target of a 75% reduction. The MiSeq i100 Series, launched in 2024 and designed with sustainability in mind, also achieved a 35% reduction in climate change impact, thanks to its reduced packaging and the room-temperature shipping and storage of its reagents.
• Operating sustainably: 100% of Illumina's global electricity consumption came from renewable sources for the third consecutive year.

Impact areas

Illumina's CSR program is rooted in four key areas, and the company's CSR report demonstrates progress made in 2024 in each:

• Accelerating access to genomics
  • Illumina launched the MiSeq i100 Series, benchtop sequencers designed for faster run times and simplified setup and analysis.
  • Illumina invested in the future of genomics by expanding access to STEM education. The company has reached 2.1 million STEM learners since 2019 through direct programming, nonprofit partners, and employee engagement.
• Nurturing our people and communities 
  • Fifty-two percent of Illumina's employees participated in giving and volunteering programs, donating 91,370 volunteer hours.
  • Illumina maintained a zero net pay gap for the sixth consecutive year.
• Integrating sustainability
  • Illumina realized a 45% decrease in scopes 1 and 2 emissions from its 2019 baseline.
  • Five Illumina labs completed the eight-month certification process with My Green Lab, the gold standard for laboratory sustainability best practices around the world.
• Operating responsibly
  • 100% of Illumina's core facilities participated in third-party audit programs.
  • Illumina was named for the sixth year in a row to the Dow Jones Best-in-Class World Index and the Dow Jones Best-in-Class North America Index (formerly part of the Dow Jones Sustainability Indices) and received a top industry ISS Corporate Governance rating.
  • Illumina continued to exercise strong corporate governance with an independent Board of Directors (all independent with the exception of the CEO) and an independent Board Chair.

The full report is available on Illumina's CSR website.

About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

Contacts

Investors:
Brian Blanchett
+1.858.291.6421
[email protected] 

Media:
Christine Douglass
[email protected]

SOURCE Illumina, Inc.